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Abstract: Primary open angle glaucoma (OAG) is a multifactorial optic neuropathy 
characterized by progressive retinal ganglion cell death and associated visual ﬁ  eld loss. OAG 
is an emerging disease with increasing costs and negative outcomes, yet its fundamental 
pathophysiology remains largely undetermined. A major treatable risk factor for glaucoma 
is elevated intraocular pressure (IOP). Despite the medical lowering of IOP, however, some 
glaucoma patients continue to experience disease progression and subsequent irreversible 
vision loss. The scientiﬁ  c community continues to accrue evidence suggesting that alterations 
in ocular blood ﬂ  ow play a prominent role in OAG disease processes. This article develops the 
thesis that dysfunctional regulation of ocular blood ﬂ  ow may contribute to glaucomatous optic 
neuropathy. Evidence suggests that impaired vascular autoregulation renders the optic nerve 
head susceptible to decreases in ocular perfusion pressure, increases in IOP, and/or increased 
local metabolic demands. Ischemic damage, which likely contributes to further impairment in 
autoregulation, results in changes to the optic nerve head consistent with glaucoma. Included in 
this review are discussions of conditions thought to contribute to vascular regulatory dysfunction 
in OAG, including atherosclerosis, vasospasm, and endothelial dysfunction.
Keywords: glaucoma, autoregulation, blood ﬂ  ow, atherosclerosis, vasospasm, endothelial 
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Introduction
Primary open angle glaucoma (OAG) is a multifactorial optic neuropathy characterized 
by progressive retinal ganglion cell death and associated visual ﬁ  eld loss. Glaucoma 
is the second leading cause of blindness worldwide (Leske 2007), yet after years of 
extensive research the exact cause of glaucomatous optic neuropathy remains elusive. 
A recent estimate suggests that roughly 80 million people will be diagnosed with glau-
coma by 2010, with 4.5 million of those suffering from bilateral blindness (Quigley 
and Broman 2006). Although elevated intraocular pressure (IOP) currently remains the 
focus of therapy, some glaucoma patients continue to experience disease progression 
despite lowering of IOP. The Early Manifest Glaucoma Trial (EMGT) showed that 
OAG disease progression rate in the treatment group was 45% as compared with 62% 
in the nontreated control group (Heijl et al 2002). In the Collaborative Initial Glau-
coma Treatment Study (CIGTS), substantial visual ﬁ  eld loss occurred in 10%–13.5% 
of participants during 5 years of follow up (Lichter et al 2001). Although IOP is still 
the only treatable OAG risk factor, it is clear that glaucoma is a complex disease that 
cannot be prevented or cured by IOP reducing therapies in all patients.
Other glaucoma risk factors that may be responsible for disease progression despite 
lowering of IOP include vascular risk factors, genetics, and other systemic conditions 
(Leske 2007). Vascular related OAG risk factors have been found in prospective, 
retrospective, and large population-based studies throughout the world. While not a 
new concept (von Graefe 1857; Hayreh et al 1970; Hayreh 2001; Flammer et al 2001), Clinical Ophthalmology 2008:2(4) 850
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disturbed ocular blood ﬂ  ow has emerged as an increasingly 
prevalent glaucoma risk factor in large population-based 
trials. Leske and colleagues (2007) recently presented new 
predictors of OAG disease progression in the EMGT trial 
including lower systolic perfusion pressure, lower systolic 
blood pressure, and cardiovascular disease history. In the 
Rotterdam eye study, patients with an ocular perfusion 
pressure lower than 50 mmHg had a four times greater risk 
of developing OAG than those with a perfusion pressure of 
80 mmHg (Hulsman et al 2007). The Egna-Neumarkt study 
found positive correlations between systemic blood pressure 
and both the diagnosis of OAG and elevated IOP (Bonomi 
et al 2000). These large scale trials compliment various data 
from smaller prospective trials which have found aging, 
systemic blood pressure, nocturnal hypotension, ocular 
perfusion pressure, migraine, disk hemorrhage, diabetes, 
and directly assessed reductions of ocular blood ﬂ  ow to be 
related to OAG. It is currently unclear whether ischemia is 
secondary to increased IOP through faulty autoregulation 
of ocular blood ﬂ  ow or if a primary vascular component 
promotes damage to the optic nerve and retinal ganglion 
cells in certain OAG patients.
Recent studies have also suggested that perfusion 
instability, rather than a progressive decline in ocular blood 
ﬂ  ow, may contribute to OAG. It is well established that 
circadian rhythms play an important role in maintaining 
homeostasis in the human body. In that capacity, OAG pro-
gression is not necessarily related to the overall level of blood 
pressure, but an abnormal vascular reaction to a reduction in 
blood pressure or increase in IOP during nonwaking hours 
(Werne et al 2008). It has been known for over four decades 
that IOP varies throughout the day, but not until recently 
has it been shown that other vascular risk factors such as 
systemic blood pressure (O’Brien 1991), ocular perfusion 
pressure (Liu et al 2003), and ocular blood ﬂ  ow (Osusky 
et al 2000) also follow circadian patterns. Ocular blood ﬂ  ow 
deﬁ  cits may therefore represent either a primary insult or are 
secondary to vascular regulatory dysfunction during diurnal 
ﬂ  uctuations in vascular risk factors in certain OAG patients 
(Grieshaber and Flammer 2005).
Blood ﬂ  ow autoregulation 
in glaucoma
Autoregulation of blood ﬂ  ow is described as the intrinsic 
capacity of an organ to maintain its blood ﬂ  ow despite 
changes in local vascular parameters (Haggendal et al 
1969). Within the eye, autoregulation is deﬁ  ned as local 
vascular constriction or dilation causing vascular resistance 
to reciprocally increase or decrease, thereby maintaining a 
constant nutrient supply in response to perfusion pressure 
changes (Harris et al 1998). Challenges to normal ocular 
blood ﬂ  ow include increased IOP, ﬂ  uctuating blood pres-
sure, a resultant decrease in ocular perfusion pressure, 
and/or a rise in local tissue metabolic demands. Failure of 
stable blood ﬂ  ow regulation may lead to ischemic damage 
of the optic nerve and/or retinal ganglion cells, which likely 
contributes to further impairment in vascular regulation. A 
cascade of events may occur, which then leads to retinal 
ganglion cell death and structural changes of the optic nerve 
head (ONH) (Flammer et al 2001) consistent with OAG 
pathophysiology (Figure 1).
Various underlying medical conditions have been pro-
posed which may contribute to ocular vascular regulatory 
dysfunction including atherosclerosis, vasospasm, and 
endothelial dysfunction. This review highlights these and 
other factors as they relate to glaucomatous optic neuropathy 
and discusses potential implications in our understanding of 
OAG disease pathophysiology and management.
Physiology of the optic nerve head 
blood ﬂ  ow autoregulation
The optic nerve is a continuation of the central nervous sys-
tem and shares several physiologic similarities with the brain, 
including blood ﬂ  ow autoregulation (Flammer and Orgul 
1998). Despite extensive research, the precise microvascular 
anatomy and blood ﬂ  ow regulation of the ONH remains dif-
ﬁ  cult to ascertain (Harris et al 2003). Several mechanisms 
involved in the vascular regulation of ocular blood ﬂ  ow that 
have been demonstrated include: metabolic, myogenic, neu-
rogenic, humoral, and endothelial-mediated factors.
Autoregulation of the cerebral circulation has been shown 
to depend largely on local blood gas perturbations (Haggendal 
et al 1969). Similarly, as ONH blood ﬂ  ow decreases, the local 
metabolic vascular response is primarily oxygen-dependent 
(Kontos et al 1978). Hyperoxia and hypocapnia mediate arte-
riolar constriction and a subsequent decrease in ONH blood 
ﬂ  ow, while hypoxia and hypercapnia result in the opposite 
response (Flammer and Orgul 1998). Additionally, the concen-
trations of K+, H+, adenosine, and intercellular osmolarity are 
known to inﬂ  uence local vascular tone (Orgul et al 1995a).
Myogenic autoregulation involves arteriolar tone changes 
through smooth muscle cell to cell signal propagation 
(Johnson 1986). Speciﬁ  cally, transmural pressure sensitive 
arteriole pacemaker cells initiate the response and although 
the exact mechanism has not been deﬁ  ned, extracellular 
calcium concentrations and endothelial factors appear to Clinical Ophthalmology 2008:2(4) 851
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contribute (Davies and Tripathi 1993). While myogenic 
autoregulation contributes to a great extent in several organs, 
most notably the colonic vasculature (Andersson 1984), its 
role in ocular tissue is still under investigation.
The autonomic nervous system orchestrates a coordinated 
response to changes in systemic physiology. In the coronary 
circulation, for example, intrinsic cardiac and extracardiac 
autonomic neurons inﬂ  uence cardiac output and coronary 
blood ﬂ  ow, often irrespective of local stimuli (Kresh and 
Armour 1997). In ocular tissue, the autonomic nervous sys-
tem contributes extensively to the retrobulbar and choroidal 
circulatory system, but the retinal and ONH vasculature lack 
direct innervation (Funk 1997). Hence, sympathetic stimula-
tion provides only indirect inﬂ  uence on OHN perfusion as 
neurogenic contribution to the vascular response is minimal 
(Harris et al 2003).
In a prototypical vascular bed, vasoactive hormones in 
the circulating blood act directly on endothelial, pericyte, and 
smooth muscle cells. The ONH, however, is exceptional in 
that it contains 1) a blood – brain barrier preventing smooth 
muscle and pericyte contact with humoral factors and 2) a 
scleral ﬂ  ange also acting as a barrier to prevent humoral 
diffusion from the choroid to the ONH (Flammer and Orgul 
1998). Hormones believed to exert an autoregulatory effect 
on the ONH by overcoming these barriers include circulat-
ing catecholamines (Yu et al 1994), vasopressin, natriuretic 
peptides, and the renin – angiotensin system (Jossi and 
Anderson 1983).
The vascular endothelium directly regulates permeability, 
but also indirectly inﬂ  uences blood vessel diameter, coagula-
tion parameters, cellular proliferation, and the inﬂ  ammatory 
cascade amongst other pathways through the release of 
vasoactive susbstances (Behrendt and Ganz 2002). Endo-
thelial mediators are increasingly reported factors in the 
regulation of ONH blood ﬂ  ow. Studies have demonstrated 
a basal formation of nitric oxide in the ocular endothelium 
that leads to active dilatation of the vasculature as well as a 
dose-dependent response relationship between endothelin-1 
and blood ﬂ  ow to the anterior optic nerve, as discussed in 
detail later (Orgul et al 1999).
Atherosclerosis
Atherosclerosis is a chronic, progressive disease affecting 
many vascular beds including the ocular circulation (Davies 
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Figure 1 A conceptual representation of the contribution of autoregulatory dysfunction to glaucomatous damage of the optic nerve head.Clinical Ophthalmology 2008:2(4) 852
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1990). It results from the deposition of lipids, inﬂ  ammatory 
cells, and connective tissue within arterial walls, leading to 
plaque formation and intimal thickening. Over time this results 
in obstruction to ﬂ  ow, compromised perfusion, and tissue 
ischemia (Davies et al 2004; de Voogd et al 2006). Recent 
research on the topic of atherosclerosis has focused on molecu-
lar and cellular mechanisms and led to a shift in the paradigm 
of disease pathophysiology (Davies et al 2004). Studies have 
shown endothelial cell dysfunction to be the ﬁ  rst detectable 
change in atherosclerotic vessels (Behrendt and Ganz 2002). 
This is supported by the observation that risk factors such as 
aging, smoking, hypertension, elevated low-density lipoprotein 
(LDL) levels, diabetes, and ischemia have been shown to alter 
endothelial function (Luscher et al 1993). Both the barrier 
and secretory function of endothelial cells are perturbed in 
atherosclerosis, aiding in plaque formation. This also manifests 
as abnormal vasoreactivity in affected vessels, suggesting a 
predisposition to ischemic insult (Bogaty et al 1994).
The current literature collectively demonstrates various 
mechanisms leading to autoregulatory dysfunction in athero-
sclerotic vessels. However, a corollary correlation between 
atherosclerosis and OAG has yet to be identiﬁ  ed. The pro-
spective Rotterdam eye study found neither atherosclerosis 
nor serum C-reactive protein (a marker of inﬂ  ammation 
associated with atherosclerosis) to be important risk factors 
for the development of OAG (de Voogd et al 2006). This is 
consistent with previous studies which were unable to ﬁ  nd 
a signiﬁ  cant relationship between atherosclerosis and OAG 
(Levene 1980; Hayreh 1993; Gasser 1998). Conversely, 
Hayreh (1999) noted that serotonin, a biomarker released 
during platelet aggregation on an atherosclerotic plaque, 
produced vasospasm of the central retinal and short posterior 
ciliary arteries in atherosclerotic monkeys. While lacking a 
control group and not performed in human subjects, Hayreh 
cites previous reports suggesting improvement of serotonin 
induced vasoconstriction after abstaining from an athero-
genic diet for several months. Further, a recent study found 
over-expression of a speciﬁ  c subset of the phospholipase A2 
enzyme family, a marker for atherosclerosis, in the ocular 
tissue of OAG patients (Ronkko et al 2007). However, this 
result may point more to the role of oxidative stress than 
atherosclerosis in OAG disease pathogenesis.
It is important to note that noninvasive measurements 
of atherosclerosis are of limited utility. The methods used 
in previous studies included echography or radiography of 
the carotid arteries to quantify intimal thickness, abdominal 
imaging to measure calciﬁ  cation in the aorta and ankle-
brachial index (de Voogd et al 2006). These techniques 
are intended to provide in vivo quantiﬁ  cation of systemic 
atherosclerosis, but measure only isolated vascular beds. 
Further, no study directly visualized the ocular circulation in 
humans, indicating a need for additional studies to accurately 
identify localized atherosclerosis and resulting changes in 
the vasculature of OAG patients.
Since atherosclerosis has a known association with other 
vascular risk factors such as aging, cerebrovascular and car-
diovascular disease, several studies have attempted to discern 
a correlation between these factors and glaucoma. A recent 
report from the EMGT indicated cardiovascular disease history 
is a newly deﬁ  ned predictor of glaucomatous disease progres-
sion (Leske et al 2007). As a systemic process, atherosclerosis 
plays a causative role in such pathology as myocardial infarc-
tion and cerebral vascular accidents. Several studies have 
reported an increased incidence of silent myocardial ischemia 
in glaucoma patients (Kaiser et al 1993; Waldmann et al 1996), 
while multiple reports link cerebral ischemia and infarct with 
glaucoma (Stroman et al 1995; Ong et al 1995; Tutaj et al 
2004). Further, the incidence of OAG, atherosclerosis, and 
ocular ischemia are known to increase with age (Harris et al 
2000). With advancing age, there is a decrease in the relative 
capillary blood ﬂ  ow, velocity, and volume within the neu-
roretinal rim and lamina cribrosa of the ONH (Boehm et al 
2005). Although multiple factors likely contribute to this pro-
cess, it has been determined that retinal arteriolar and venular 
diameters narrow during normal aging due to age-associated 
vascular rigidity and atherosclerosis (Leung et al 2003). This 
prevents the elderly population from having the same capacity 
to alter vessel diameter and thus blood ﬂ  ow as a function of 
autoregulation (Wong et al 2003). This may help explain the 
observation that endothelial function of the retinal vasculature 
improves with angiotension AT1 receptor blockade in young 
patients, but shows no response in older individuals (Delles 
and Schmieder 2004; Oehmer et al 2006).
In summary, atherosclerosis has been demonstrated to 
cause autoregulatory dysfunction in multiple vascular beds 
resulting in signiﬁ  cant vascular disease pathologies. Although 
a relationship between certain atherosclerotic risk factors and 
OAG has been reported, the direct inﬂ  uence of atheroscle-
rosis on the progression of glaucoma is undetermined. More 
research is required to understand how atherosclerosis, car-
diovascular disease, age, and blood ﬂ  ow autoregulation are 
inter-related in OAG disease pathophysiology.
Vasospasm
Vasospasm is characterized as a sharp, exaggerated, and 
often persistent contraction of a blood vessel, resulting in Clinical Ophthalmology 2008:2(4) 853
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a reduction in luminal diameter and respective blood ﬂ  ow 
(Mchedlishvili 1981). This vasoconstriction or insufﬁ  cient 
dilatation of the microcirculation may lead to inadequate 
blood ﬂ  ow to the surrounding tissue and consequent ischemia. 
Simultaneous arterial or venous dilatations in neighboring 
vascular beds may be a by-product of vascular dysregulation 
in vasospastic individuals (Flammer 1998). Certain organs, 
such as the heart, brain, and eye produce clinically apparent 
spasms more regularly than other organ systems.
Vasospasm has been associated as a secondary ﬁ  nding 
in multiple disease states including multiple sclerosis, lupus 
erythematosus, antiphospholipid syndrome, rheumatoid 
arthritis, giant cell arthritis, Behcet’s disease, Crohn’s dis-
ease, Buerger’s disease, Raynaud’s disease, prinzmetal’s 
angina, preeclampsia, and AIDS (Gasser 1991; Flammer 
et al 2001). However, a primary vasospastic syndrome has 
also been discovered wherein patients without an underlying 
disease develop vasospasm in response to stimuli such as 
cold or emotional stress (Gasser et al 1990). This disorder 
is of particular interest since the most commonly reported 
organ involving vasospasm is the eye (Gasser 1991). This 
syndrome is found more frequently in women than men 
(Flammer and Prunte 1991), which possibly correlates with 
the observation that normal tension glaucoma (NTG) is twice 
as common in women. Furthermore, the female gender is 
considered an independent risk factor for visual ﬁ  eld loss 
progression in NTG (Orgul et al 1994; Drance et al 2001). 
The increased susceptibility in females may be due to falling 
estrogen levels, which are known to have a vasoprotective 
effect and are reduced post-menopause (Siesky et al 2008). 
Similarly, vasospasm is also observed more commonly in 
Japanese than Caucasian patients and correspondingly, NTG 
is found more commonly in Japan than most other countries 
(Beltrame et al 1999; Flammer et al 2001). These and vari-
ous other studies suggest that vasospasm may exemplify a 
speciﬁ  c mechanism by which glaucomatous changes can 
occur (Kaiser et al 1993a; Nicolela et al 1996; Gasser 1998; 
Anderson et al 1999; Flammer et al 2001). Vasospasm can 
create an environment of blood ﬂ  ow dysregulation which 
increases the vulnerability of the ONH to vascular challenges, 
leading to perfusion instability, ischemic changes, axonal 
loss, and changes of the ONH.
The most prevalent clinical signs and symptoms of 
vasospasm are cold hands and feet, low blood pressure, 
and migraine (Gasser 1989, 1998; Gasser et al 1990; Orgul 
et al 1995b; Flammer et al 2001). A systematic diagnosis of 
vasospasm syndrome has yet to be deﬁ  ned, but it has been 
suggested that ﬁ  nger or nail blood ﬂ  ow response to cold 
provocation can be diagnostic (Drance et al 1998; Gasser and 
Flammer 1991). It is important to note that patients with glau-
coma who have been shown to have evidence of vasospasm 
were more likely to demonstrate worsening of visual ﬁ  elds 
following cooling than nonvasospastic patients (Nicolela 
et al 2003). This suggests that vasospasm may manifest itself 
in clinically relevant glaucomatous deterioration in certain 
individuals. Migraine, often characterized as a vasospastic 
disorder, is more commonly found in females and has a well 
documented association with NTG (Cursiefen et al 2000). It 
has been demonstrated as a risk factor for the progression of 
visual ﬁ  eld loss, suggesting a common underlying vascular 
pathology for both conditions (McKendrick et al 2000). Also 
frequently associated with vasospasm, low blood pressure is 
a reported risk factor for glaucoma, but if systemic hypoten-
sion is secondary to vasospasm or an unrelated phenomenon 
remains uncertain (Kaiser et al 1993b; Gass et al 1997; 
Gasser 1998; Pache et al 2003). It has been shown that blood 
pressure variations away from normal physiologic nocturnal 
dips are correlated with vasospasm, OAG, and NTG (Werne 
et al 2008). The failure of ocular blood ﬂ  ow to remain con-
stant during physiological challenges may manifest itself as 
ocular vasospasm or represent primary vascular dysregula-
tion during vasospastic episodes.
Vasospasm is a transient phenomenon that is potentially 
reversible, allowing the restoration of steady-state perfusion. 
Due to its time-dependent nature, baseline blood ﬂ  ow mea-
surements may not demonstrate any abnormalities compared 
with controls (Gugleta et al 2003). Therefore, the use of a 
provocation test to unmask underlying vascular dysregulation 
has been proposed in ocular hemodynamic measurements 
(Gugleta et al 2005). Studies have been conducted to dem-
onstrate this reversibility. Increased visual ﬁ  eld deﬁ  cits have 
been demonstrated after cold water provocation in vasospas-
tic patients that decreased with the administration of calcium 
channel blockers or magnesium (Gasser et al 1990; Gasser 
and Flammer 1990; Gaspar et al 1995). Likewise, treatment 
with calcium channel blockers has been shown to improve 
retrobulbar hemodynamics in some patients with NTG 
(Harris et al 1997). In addition to calcium channel blockers, 
hyperoxia and elevated carbon dioxide (CO2) breathing are 
sometimes utilized to assess vascular reactivity. While stud-
ies investigating the retinal circulatory response to blood gas 
perturbations report conﬂ  icting results (Gugleta et al 2003), 
reports consistently indicate CO2 inhalation provides a revers-
ible improvement in visual ﬁ  eld defects and a decrease in 
the resistive indices of orbital vessels (Wilson et al 1997; 
Niwa et al 2000). Speciﬁ  cally, Harris and colleagues (1994) Clinical Ophthalmology 2008:2(4) 854
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showed that NTG patients had signiﬁ  cantly lower ophthalmic 
artery blood ﬂ  ow velocities and higher vascular resistance 
than controls. The differences between NTG and controls 
were reversed during elevated CO2 breathing, suggesting the 
presence of a reversible vasospasm in the NTG cohort (Harris 
et al 1994). A study by Gugleta and colleagues (2005) found 
women with vasospasm demonstrated an inverse response 
pattern of choroidal and ONH blood gas perturbations com-
pared with women without vasospasm. The authors suggest 
that vasospastic patients may have diminished autoregula-
tory capacity or increased responsiveness to CO2 in certain 
vascular beds. A differentiation of normal and abnormal 
blood ﬂ  ow regulation during blood gas perturbations and 
calcium channel blockers may demonstrate which persons 
are at greatest risk for vasospasm, impaired ocular blood 
ﬂ  ow and possibly OAG.
The current body of literature suggests that vasospasm 
may play a more signiﬁ  cant role in OAG ONH damage than 
atherosclerosis. Although both conditions have been shown 
to contribute to systemic autoregulatory dysfunction, it is 
hypothesized that most patients with increased vascular 
resistance secondary to atherosclerotic change compensate 
with proﬁ  cient autoregulation in small arterioles and capil-
laries (Flammer et al 1999). Intracranial vessels seem more 
resistant to the development of atherosclerosis in comparison 
to other vascular beds (Faraci and Heistadt 1998). While 
effects of atherosclerosis are readily apparent on fundoscopic 
exam, relying on these changes for measure of systemic and 
retinal disease may be of limited utility (Helvaci et al 2007). 
It is believed that perfusion ﬂ  uctuates more dramatically in 
vasospastic patients, which can additionally lead to reperfu-
sion damage (Schempp and Elstner 1998).
The concept of vasospasm-induced reperfusion injury is 
heavily emphasized in other ﬁ  elds of research including vas-
cular and transplant surgery (Jokuszies et al 2006), neurology 
(Reid et al 1995), and cardiology (Laude et al 2004). During 
myocardial ischemia and infarction, for example, reperfusion 
is characterized by the overproduction of oxygen-derived free 
radicals that spurn an acute inﬂ  ammatory response and tissue 
degradation. It has also been argued that reperfusion injury 
alters the endothelium architecture, allowing for such adverse 
conditions as vasospasm and atherosclerosis to develop more 
readily (Laude et al 2004).
In summary, vasospasm is associated with multiple dis-
ease states including OAG with NTG patients and women 
appearing to be the most at risk for vasopastic contributions 
to disease processes. Vasospasm may result in ﬂ  uctuations 
in ocular perfusion, ischemia, and/or reperfusion injury to 
the ocular tissues. Importantly, vasospasm may be reversible 
(treatable). The capacity of diagnostic testing for OAG risk 
using blood gas perturbations should be further explored, 
especially in patients that demonstrate a vasospastic pro-
pensity.
Endothelial dysfunction
Endothelial dysfunction has been increasingly implicated in 
OAG disease pathophysiology. Disruption of the homeostatic 
factors maintaining physiologic vessel caliber may shift the 
balance toward an excess of vasoconstriction over vasodila-
tion resulting in vasospasm (Delaney et al 2006). Similarly, 
atherosclerosis changes endothelial architecture and disrupts 
mechanisms contributing to endothelium-derived vascular 
relaxation (Faraci and Heistadt 1998). A causative and/or 
synergistic role involving atherosclerosis, vasospasm, and 
endothelial dysfunction may result in dysfunctional regula-
tion of the ocular vasculature potentially contributing to 
OAG pathophysiology.
The vascular endothelium regulates the microcirculation 
through release of vasoactive factors, the most potent of 
which are the vasodilator nitric oxide (NO) and the vaso-
constrictor endothelin-1 (ET-1) (Adams 2006). Additional 
endothelium-derived activating compounds include prosta-
cyclins, acetylcholine, bradykinin, and histamine (Flammer 
and Orgul 1998; Adams 2006). In endothelial cells, NO 
synthase (NOS) catalyzes the conversion of L-arginine to 
NO and L-citrulline. NO released from endothelial cells 
directly stimulates the surrounding vascular smooth muscle 
to promote vasodilation (Toda and Nakanishi-Toda 2007). 
Systemic factors such as hyperlipidemia, atherosclerosis, 
and hyperglycemia impair endothelial NO signaling through 
oxidative stress damage (Napoli et al 2001). Plasma levels 
of asymmetric dimethylarginine, an endogenous inhibitor 
of NOS, are disproportionately elevated in hyperlipidemia, 
hyperhomocystinemia, atherosclerosis, coronary artery dis-
ease, hyperglycemia, and other disorders affected by endo-
thelial dysfunction (Miyazaki et al 1999; Delaney et al 2006). 
Conversely, infusions of L-arginine, a precursor molecule 
to NO, limit injury from ischemia, and reperfusion-induced 
endothelial dysfunction (Pernow et al 2003).
It is known that NO activity contributes to ocular auto-
regulation and can protect the endothelium and nerve ﬁ  ber 
layer against pathologic stressors implicated in glaucoma, 
ischemia, and diabetes (Toda and Nakanishi-Toda 2007). A 
recent report by Polak and colleagues (2007) presents the 
ﬁ  rst in vivo evidence for altered ocular L-arginine/NO 
pathway in glaucoma patients. Polymorphisms in the Clinical Ophthalmology 2008:2(4) 855
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endothelium speciﬁ  c NOS (eNOS) have been found in 
familial patients with glaucoma (Tunny et al 1998). A pre-
liminary study by Wiggs and colleagues also suggests the 
presence of a polymorphism in the eNOS gene in patients 
with high and NTG that predisposes these patients to supe-
rior paracentral ﬁ  eld loss (Delaney et al 2006). Decreased 
levels of cyclic GMP, an indicator of NO activity, have 
been demonstrated in the plasma and aqueous humor of 
glaucoma patients, with corresponding lower systolic and 
diastolic ophthalmic artery blood ﬂ  ow velocities of NTG 
patients (Laude et al 2004).
Opposing the vasodilation properties of NO is ET-1, 
the most important and potent vascular constricting factor. 
The peptide is synthesized by endothelial cells and either 
binds to the ETA receptor on smooth muscle cells to mediate 
vasoconstriction or binds to the ETB receptor on endothelial 
cells to mediate vasodilation via the autocrine release of NO, 
prostacyclin and by increasing removal of endothelin from 
the circulation. (Figure 2) Although this indicates ET-1 can 
stimulate either vasoconstriction or vasodilation, the overall 
response in vivo is sustained and powerful vasoconstric-
tion (Rubanyi and Polokoff 1994). There is evidence that 
enhanced ET-1 vasoconstriction is involved in the pathology 
of such conditions as hypertension, heart failure, myocardial 
infarction, renal failure, and secondary vasospastic disorders 
(Ortega and de Artinano 1997).
A number of studies have investigated the role of ET-1 
in glaucoma. ET-1 has been shown to decrease blood ﬂ  ow 
to the anterior optic nerve when directly applied to this 
region (Orgul et al 1996). It has been determined that ET-1 
provokes forceful contractions of isolated ophthalmic arter-
ies with smaller vessels expressing greater ET-1 sensitivity 
(Haeﬂ  iger et al 1992; Polak et al 2003). Utilizing arteries 
dissected from gluteal fat biopsies, Buckley and colleagues 
(2002) identified dysfunction of the systemic vascular 
endothelial cell in patients with NTG by demonstrating 
decreased responsiveness to ET-1 stimulation. Alterations in 
the vascular responsiveness to ET-1 or changes in synthesis, 
activation, and removal of the molecule may therefore result 
in impaired regulation of ocular blood ﬂ  ow. Several studies 
have demonstrated increased plasma ET-1 levels in NTG 
patients (Sugiyama et al 1995; Kaiser et al 1995), but these 
results have not been reproduced in patients with high tension 
glaucoma (HTG) (Tezel et al 1997). Aqueous humor levels 
of ET-1 are reportedly elevated in HTG (Noske et al 1997) 
and one study demonstrated a signiﬁ  cant elevation of plasma 
ET-1 in HTG when the subjects were moved from the supine 
to upright position (Kaiser et al 1997). To further support a 
role for vasospasm in endothelial dysfunction, Nicolela and 
colleagues (2003) reported an abnormal increase in plasma 
ET-1 in response to body cooling in OAG patients. This 
suggests a hyperactive production and/or release of ET-1 
Endothelium
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ET-1
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ET-1
Vasoconstriction Vasodilation
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Figure 2 A schematic diagram of the known effects of endothelin-1 on the endothelium and smooth muscle. The dashed line indicates an inhibitory effect.
Abbreviations: ET-1, endothelin-1; NO, nitric oxide; PC, prostacyclin; ETA, endothelin-A receptor, ETB, endothelin-B receptor.Clinical Ophthalmology 2008:2(4) 856
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in response to vasospastic stimuli in predisposed patients 
(Nicolela et al 2003).
Several recent studies have shifted the focus from solely 
examining ET-1 expression to investigating the role of ETA 
and ETB receptors in ocular blood ﬂ  ow. In studies of porcine 
eyes, ET-1 increases ocular blood ﬂ  ow at negligible doses 
and reduces it at higher ones, which is thought to occur sec-
ondary to activation of ETB and ETA receptors, respectively 
(Yao et al 1991). This suggests that low ET-1 doses have a 
greater afﬁ  nity for ETB receptors to cause vasodilation, but 
increased levels of ET-1 leads to vasoconstriction by binding 
to ETA receptors. Blocking ETA receptors to the exogenous 
administration of ET-1 in humans has been shown to reverse 
the observed reduction in retinal blood ﬂ  ow, further indicat-
ing that ETA receptors mediate the vasoconstrictive effects 
of ET-1 in the retina (Sugiyama et al 1995). In patients with 
NTG, Henry et al reported normal vasoreactivity to ET-1, 
but signiﬁ  cantly decreased vasodilation in response to ETA 
receptor antagonism. The authors suggest this response may 
be due to a combination of diminished ETA receptor-mediated 
tone, increased ETB receptor mediated contraction, or 
impaired release of NO (Henry et al 2006). Correspondingly, 
polymorphisms of the ETA receptor have been associated 
with NTG (Kim et al 2006).
ETB receptor polymorphisms, however, have yet to show 
any signiﬁ  cant association with systemic or ocular disease 
(Delaney et al 2006). The role of ETB in vascular physiology 
is shown to be selectively dependent on the tissue bed. It has 
been demonstrated in both rat and monkey models of sub-
arachnoid hemorrhage that increased smooth muscle cell ETB 
receptor expression induces vasospasm of cerebral vessels 
(Hino et al 1996; Hansen-Schwartz et al 2003). Conversely, 
the function of ETB in human skin seems insigniﬁ  cant (Lipa 
et al 1999). The role of ETB in ocular hemodynamics is yet 
to be determined, but similar to other vascular beds in the 
body, it is likely inﬂ  uenced by the proportion of endothelial 
to smooth muscle cells and corresponding ETA/ETB ratio 
(Delaney et al 2006).
In addition to directly reducing ocular blood ﬂ  ow, ET-1 
increases local vascular sensitivity to other vasoconstric-
tive elements such as angiotensin II and catecholamines 
(Schmetterer 1997). Grieshaber and Flammer (2005) suggest 
that the elevation of ET-1 in glaucoma represents an epiphe-
nomenon rather than a distinctive mechanism. They point 
to the observation of signiﬁ  cantly elevated ET-1 levels in 
vasospastic and systemic diseases such as multiple sclerosis, 
rheumatoid arthritis, ﬁ  bromyalgia, and Susac syndrome. 
Although a pale ONH is often associated with these diseases, 
glaucoma does not occur more frequently in these patients 
than in the average population. This suggests that ET-1 
upregulation may be secondary to repetitive perfusion insuf-
ﬁ  ciency and damage occurring not only in the ONH, but 
also subclinically in multiple organs (Waldmann et al 1996; 
Grieshaber and Flammer 2005). Although animal models have 
suggested that increased levels of ET-1 by itself can lead to 
glaucoma via ischemia (Ciofﬁ   et al 2004), these same results 
have not been demonstrated in human population studies.
In summary endothelial dysfunction is likely related to 
glaucoma, but the exact role of mediators such as NO, NOS, 
ET-1, and ETA/ETB in OAG pathophysiology has yet to be fully 
appreciated. Endothelial dysfunction may therefore be primary 
or secondary to vascular diseases including atherosclerosis and 
vasospasm in its contribution to OAG pathology.
Blood pressure changes 
and blood ﬂ  ow
Fluctuations in IOP, blood pressure, ocular perfusion pres-
sure, and thus blood ﬂ  ow are implicated in OAG. A patient 
with vasospastic syndrome may not be able to compensate 
for elevations of IOP and/or blood pressure dips, while 
a healthy patient can autoregulate to maintain consistent 
ocular perfusion. While not detailed in this review, several 
studies have found a modest association between OAG and 
hypertension (Tielsch et al 1995; Bonomi et al 2000; Mitchel 
2004), while others found no signiﬁ  cant relationships (Leske 
et al 1996, 2008). Choi and colleagues (2007) investigated 
24-hour IOP, blood pressure, and perfusion pressure changes 
associated with clinically relevant visual ﬁ  eld outcomes. 
The study determined that both anatomic (retinal nerve 
ﬁ  ber layer thickness) and functional (visual ﬁ  eld) outcome 
variables were signiﬁ  cantly worse in glaucoma patients 
with wider circadian perfusion pressure ﬂ  uctuations. The 
authors attributed glaucoma progression to daily repetitive 
ischemic insults followed by reperfusion injury in eyes 
through dysfunctional regulation mechanisms that could 
not maintain consistent perfusion pressure (Choi et al 2007). 
In the Thessaloniki Eye Study, patients without glaucoma 
having a diastolic blood pressure of 90 mm Hg with 
antihypertensive treatment was associated with increased 
cupping and decreased rim area of the optic disk (Topouzis 
et al 2006). A recent report from the European Glaucoma 
Prevention Study (EGPS) indicates that systemic diuretic 
use was associated with the development of OAG (Miglior 
et al 2007). This may be due to the inability of the eye to 
maintain consistent, adequate perfusion during pharmaco-
logically lowered blood pressure in susceptible individuals. Clinical Ophthalmology 2008:2(4) 857
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A detailed review of ﬂ  uctuations in blood pressure, IOP, 
ocular perfusion pressure and blood ﬂ  ow are covered in 
great detail elsewhere (Werne et al 2008).
Diabetes and glaucoma
Other vascular diseases, such as diabetes, have conﬂ  icting 
reports about a potential role in OAG pathology (Leske 
et al 2007), although a signiﬁ  cant correlation with diabetes 
was determined by a meta-analysis (Bonovas et al 2004). 
Diabetes, a disease with many vascular complications, 
has been reported to be related to glaucoma, however the 
evidence for diabetes as a contributing factor in OAG 
pathology is currently lacking. Population-based studies, 
such as the Baltimore eye survey, the Barbados eye study, 
and the Rotterdam study failed to support an association 
between diabetes and glaucoma. The relationship with 
other vascular risk factors are even less well deﬁ  ned, with 
a previous review indicating no consensus between OAG 
and smoking, hypercholesterolemia, or body mass index 
(Flammer et al 1999).
The role of other vascular diseases in glaucoma remains 
unclear. How each disease is related to ocular vascular 
regulation, or lack thereof, is uncertain. It is possible that 
understanding how OAG patients react differently to physi-
ological challenges than healthy controls may reveal the 
differences reported in the literature. It is also possible that 
diabetes and hypercholesterolemia, while vascular in nature, 
do not directly inﬂ  uence ocular vascular regulation in a 
capacity that contributes to OAG.
Clinical and therapeutic 
implications
With evidence supporting vascular risk factors in glaucoma-
tous optic neuropathy, the medical community may choose 
to modify the focus of OAG disease characterization and 
management. Certain patients with glaucoma demonstrate 
vascular regulatory dysfunction. Physiologic phenom-
enons, such as circadian variations of IOP, ocular perfusion 
pressure, and ocular blood ﬂ  ow are generating increasing 
evidence for their role in ocular ischemia and OAG disease 
processes (Werne et al 2008). Systemic medications such 
as antihypertensives have been shown to exacerbate OAG 
changes, indicating a need for heightened awareness of 
medication regimens in the glaucoma patient population 
(Netland et al 1997).
To screen for a primary vasospastic disorder, a 
recent review recommends practitioners include ques-
tions regarding a history of cold hands/feet, migraine or 
hypotension in patients (Delaney et al 2006). A thorough 
assessment of vascular risk factors including a history of 
cardiovascular disease may assist in predicting disease 
progression and in improving management in identiﬁ  ed 
patients (Leske et al 2007).
Several vascular pharmacological targets have been 
identified in preliminary therapeutic trials for vascular 
dysfunctional regulation. Calcium channel blockers have 
been shown to improve outcomes in vasospastic-induced 
secondary ischemia in patients with subarachnoid hemor-
rhage (Mees et al 2007) and intractable migraine (Ng et al 
2000). Authors have demonstrated calcium channel blocker-
induced relief of coronary spasm following coronary artery 
bypass grafting (Caputo et al 1999), with one study suggest-
ing injection of calcium blockers whenever there is reason 
to suspect vasospasm in arterial grafts (He et al 2000). In 
ocular ischemia, calcium channel antagonists can be indi-
cated in the treatment of the ocular ischemia syndrome and 
amaurosis fugax (Winterkorn et al 1993; Winterkorn and 
Beckman 1995). Similarly, calcium channel blockers may 
reduce ocular vasospasm in certain glaucoma patients (Harris 
et al 1997; Flammer et al 1999). Several studies show that 
calcium channel antagonists reduce the effect of increased 
levels of ET-1 on ocular perfusion and improve visual ﬁ  eld 
defects through induced vasodilation (Flammer et al 2001). 
Magnesium also reduces ET-1-induced vasospasm and 
although it is actively being pursued in the management 
of subarachnoid hemorrhage, its usefulness in glaucoma is 
currently unknown (Dettmann et al 1998; Mees et al 2007). 
Blood gas changes, including elevated CO2 breathing may 
also be used to test for vasospastic tendency and/or revers-
ibility (Harris et al 1994).
The contribution of NO in the treatment of vascular 
dysfunctional regulation is becoming increasingly apparent. 
Investigations into cerebral vasospasm following cerebral 
vascular insults have demonstrated reduced vasospasm and 
ischemia-reperfusion injury with nitrate infusion (Pluta et al 
2005; Jung et al 2006). The stroke literature has recently 
highlighted a role for initiating or continuing statin therapy 
in patients with vasospasm and ischemia-reperfusion injury 
(Endres and Laufs 2006; Trimble and Kockler 2007). These 
medications are thought to produce a local effect through 
upregulation and activation of eNOS to increase NO produc-
tion (Tseng et al 2005). NO has also been shown to protect 
the liver and heart against reperfusion injury, with one report 
suggesting a role for daily dietary nitrite and nitrate therapy 
for optimal cardiovascular health (Bryan et al 2007). Studies 
concerning ocular health have demonstrated that systemic Clinical Ophthalmology 2008:2(4) 858
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nitroglycerin preparations have a protective effect against 
optic neuropathy in glaucoma patients taking the medication 
for nonophthalmic reasons (Zurakowski et al 1998). Acute 
intravenous and oral administration of nitroglycerine lowers 
IOP in both glaucoma and healthy patients, with a transient 
increase in ocular blood ﬂ  ow (Wizemann and Wizemann 
1980; Sinclair et al 1993). The L-arginine/NO/cyclic GMP 
pathway has also been implicated in the IOP decrease (Kanno 
et al 2000). Chronic exposure to NO may actually contribute 
to glaucomatous progression (Toda and Nakanishi-Toda 
2007), indicating a potential role for NOS inhibition or a 
potential for downregulation or insensitivity. For example, 
inducible NOS (iNOS) is expressed only during inﬂ  amma-
tion and other pathological responses resulting in abundant 
NO production and eventual retinal ganglion cell loss (Toda 
and Nakanishi-Toda 2007). Animal trials of iNOS selective 
inhibition have demonstrated signiﬁ  cantly lower retinal gan-
glion cell loss in treated versus untreated subjects (Neufeld 
et al 1999). It is therefore recommended that future efforts 
continue to elucidate the role of NO and its use in potential 
therapeutic interventions.
In a similar fashion, the known effect of endothelin 
on systemic and ocular circulation has led to a number of 
studies investigating potential therapeutic strategies. The 
pharmaceutical industry has recognized the importance of 
this biomolecule and an increasing number of ETA speciﬁ  c 
antagonists are undergoing trials for the management of 
hypertension (D’Orleans-Juste et al 2002). Preliminary 
studies also suggest this selective antagonism maintains 
endothelin’s role in vascular relaxation (Takase et al 1995). 
Endothelin mediated pathology has been demonstrated in the 
ocular circulation, although application of this knowledge to 
disease therapy is currently limited.
Conclusion
Glaucoma is a comprehensive term for a heterogeneous 
disease comprising multiple etiologies. Alterations in ocular 
blood ﬂ  ow have become increasingly implicated in OAG 
disease pathology. The current body of literature suggests 
several possible mechanisms may be involved in the vas-
cular regulatory dysfunction of OAG patients, although 
an inclusive appreciation from the molecular level to the 
clinically apparent is incomplete. Generalized vascular 
diseases, including endothelial dysfunction, atherosclerosis, 
and vasospasm may contribute to OAG disease pathophysi-
ology. Patients suffering from vascular impairment, and 
therefore, faulty regulation of blood ﬂ  ow may be unable to 
compensate for physiologic ﬂ  uctuations in IOP and blood 
pressure to maintain ocular perfusion pressures. This may 
result in chronic, intermittent ischemic and reperfusion dam-
age to the ONH, which contributes to glaucomatous optic 
neuropathy. Continuing research is needed to discern the 
signiﬁ  cance of the vascular factors presented in this text, 
along with others not mentioned or unknown. Long-term 
multicenter clinical trials investigating the relationship 
between vascular dysregulation in glaucoma patients and 
nonclinical outcomes such as visual function and optic nerve 
changes are necessary.
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